Meeting
2024 ASCO Genitourinary Cancers Symposium
Efficacy, safety, and tolerability of tivozanib (TIVO) in heavily pretreated patients (pts) with advanced clear-cell renal cell carcinoma (ccRCC).
Authors
Andrew Johns
Department of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX
Andrew Johns , Matthew T Campbell , Mamie Gao , Zita Dubauskas Lim , Emily Wang , Andrew Warren Hahn , Jianjun Gao , Amishi Yogesh Shah , Pavlos Msaouel , Nizar M. Tannir
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session C: Renal Cell Cancer; Adrenal, Penile, and Testicular Cancers
Track
Renal Cell Cancer,Adrenal Cancer,Penile Cancer,Testicular Cancer
Sub Track
Therapeutics
Citation
J Clin Oncol 42, 2024 (suppl 4; abstr 419)
DOI
10.1200/JCO.2024.42.4_suppl.419
Abstract #
419
Poster Bd #
G22
Abstract Disclosures
Similar Posters
Poster
2021 Genitourinary Cancers Symposium
Cabozantinib (Cabo) beyond progression improves survival in advanced renal cell carcinoma patients: The CABEYOND study (Meet-Uro 21).
First Author: Giuseppe Procopio
Poster
2023 ASCO Genitourinary Cancers Symposium
A pilot trial evaluating the rapid sequencing of approved therapies in patients (pts) with advanced clear cell renal cell carcinoma (ccRCC).
First Author: Qian Qin
Poster
2022 ASCO Genitourinary Cancers Symposium
Effectiveness of first-line therapy in patients with advanced non-clear renal cell carcinoma (nccRCC).
First Author: Sophie Laramee
Poster
2021 Genitourinary Cancers Symposium
Effectiveness of first-line immune checkpoint inhibitors (ICI) in advanced non-clear cell renal cell carcinoma (ccRCC).
First Author: Jeffrey Graham